Results 201 to 210 of about 39,929 (263)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Serum villin‐1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in acutely decompensated cirrhosis. Incorporating villin‐1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
David Tornai   +22 more
wiley   +1 more source

Graft-vs.-Host Disease

Critical Reviews in Oral Biology & Medicine, 1997
Bone marrow transplantation (BMT) is the treatment of choice for many leukemias, lymphomas, bone marrow failure syndromes, and immundeficiency disorders, and is the primary and salvage therapy for many solid malignancies. With the establishment of national and international marrow banks, unrelated allogeneic BMT is being performed with increasing ...
S B, Woo, S J, Lee, M M, Schubert
openaire   +2 more sources

Chronic Graft-vs-Host Disease

JAMA, 2003
ALLOGENEIC HEMATOPOIETIC cell transplantation (HCT) is a treatment used increasingly for a variety of malignant and nonmalignant diseases of the bone marrow and immune system. Although the procedure cures many patients with otherwise incurable diseases, it is often associated with serious immunological complications, particularly graft-vs-host disease (
Vikas, Bhushan, Robert H, Collins
openaire   +2 more sources

Hepatitic Variant of Graft-vs-Host Disease

American Journal of Clinical Pathology, 2022
Abstract Objectives Graft-vs-host disease (GVHD) of the liver is a complication of allogeneic hematopoietic stem cell transplantation with hepatitic and classic variants. We determined the percentage of hepatitic variant cases, compared clinicopathologic features of the two groups, and assessed ...
Tom Z Liang   +5 more
openaire   +2 more sources

Mucosal graft‐vs‐host disease

Oral Diseases, 2007
Graft‐vs‐host disease (GVHD) is a serious complication of hematopoietic stem cell transplantation (HSCT). Indications for HSCT have greatly expanded, and more patients are undergoing HSCT today than ever before. In addition, the options for immunosuppressive therapy for both prevention and treatment of GVHD have also expanded.
J, Lew, J A, Smith
openaire   +2 more sources

Ocular Graft vs. Host Disease

The Ocular Surface, 2005
Acute graft vs host disease (GVHD) is thought to be mainly a Th1 inflammatory-mediated process, whereas chronic GVHD involves primarily Th2 inflammation. To elucidate new strategies for the treatment and prevention of ocular GVHD, it is important to understand the pathophysiologic connection between systemic and organ-specific acute and chronic GVHD ...
openaire   +2 more sources

Syngeneic Graft-vs-Host Disease

Archives of Dermatology, 1987
Graft-vs-hostD) can be a lethal complication of bone marrow transplantation. The acute form of the disease most often occurs by day 60 after transplant and may affect any or all of three major target organs, namely, skin, liver, and gastrointestinal ointestinal tract.1y ute GVHD terized by a dermatitis that begins as a pruritic macular exanthem on the ...
openaire   +2 more sources

Life-threatening graft-vs-host disease

Clinics in Dermatology, 2005
Hematopoietic stem cell transplant (SCT) is considered standard therapy for a variety of malignant and nonmalignant diseases. Graft-versus-host disease (GVHD) still represents today a major complication of hematopoietic SCT. Two types of GVHD have traditionally been recognized on the basis of the time of onset following transplantation, distinct ...
Erich, Vargas-Díez   +3 more
openaire   +2 more sources

Graft-vs-Host Disease

2000
The transplantation of healthy hematopoietic stem cells into a patient with aplastic anemia or leukemia is potentially curative therapy, but the development of acute graftvs-host disease (GVHD), which often occurs even when the donor and recipient are siblings fully matched at the human leukocyte antigen (HLA) loci, significantly limits survival.The ...
Thomas R. Spitzer, Robert Sackstein
openaire   +1 more source

Graft-vs-host disease

Bone Marrow Transplantation, 2005
JLM Ferrara, KR Cooke and HJ Deeg (eds) Third edition, 2005. Marcel Dekker, New York, NY, USA, ISBN: 0-8247-5472-7, 645pp.
openaire   +1 more source

Home - About - Disclaimer - Privacy